126 related articles for article (PubMed ID: 35217486)
1. Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents.
Mariottini A; Forci B; Gualdani E; Romoli M; Repice AM; Barilaro A; Mechi C; Massacesi L; Francesconi P
Mult Scler Relat Disord; 2022 Apr; 60():103679. PubMed ID: 35217486
[TBL] [Abstract][Full Text] [Related]
2. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
3. The retirement rate due to multiple sclerosis has decreased since 1995- A retrospective study in a Finnish central hospital.
Heinonen T; Castrén E; Luukkaala T; Mäkinen K; Ruutiainen J; Kuusisto H
Mult Scler Relat Disord; 2020 Oct; 45():102360. PubMed ID: 32688302
[TBL] [Abstract][Full Text] [Related]
4. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
5. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
6. Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: a registry-based linkage study.
Willumsen JS; Grytten N; Aarseth J; Myklebust TÅ; Myhr KM; Midgard R
J Neurol Neurosurg Psychiatry; 2022 Sep; 93(11):1154-61. PubMed ID: 36096665
[TBL] [Abstract][Full Text] [Related]
7. Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.
Knapp R; Hardtstock F; Wilke T; Maywald U; Chognot C; Craveiro L; Rouzic EM
Mult Scler Relat Disord; 2023 Apr; 72():104583. PubMed ID: 36905817
[TBL] [Abstract][Full Text] [Related]
8. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
Balcom EF; Smyth P; Kate M; Vu K; Martins KJB; Aponte-Hao S; Luu H; Richer L; Williamson T; Klarenbach SW; McCombe JA
J Neurol Sci; 2024 Mar; 458():122913. PubMed ID: 38335712
[TBL] [Abstract][Full Text] [Related]
10. A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.
Lanzillo R; Sparaco M; Lavorgna L; Carmisciano L; Signoriello E; Signori A; Costabile T; Maniscalco GT; Saccà F; Cepparulo S; Russo CV; Bisecco A; Frattaruolo N; Strianese A; Lus G; Brescia Morra V; Bonavita S
Neurol Sci; 2020 Nov; 41(11):3235-3241. PubMed ID: 32388646
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study.
Nørgaard M; Veres K; Didden EM; Wormser D; Magyari M
Mult Scler Relat Disord; 2019 Feb; 28():81-85. PubMed ID: 30576846
[TBL] [Abstract][Full Text] [Related]
12. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
13. As time goes by: Treatment challenges in elderly people with multiple sclerosis.
Gelibter S; Saraceno L; Pirro F; Susani EL; Protti A
J Neuroimmunol; 2024 Jun; 391():578368. PubMed ID: 38761652
[TBL] [Abstract][Full Text] [Related]
14. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington.
Rice J; Hildebrand A; Spain R; Senders A; Silbermann E; Wooliscroft L; Yadav V; Bourdette D; Cameron M
Mult Scler Relat Disord; 2021 Oct; 55():103172. PubMed ID: 34332457
[TBL] [Abstract][Full Text] [Related]
16. [State of health of populations residing in geothermal areas of Tuscany].
Minichilli F; Nuvolone D; Bustaffa E; Cipriani F; Vigotti MA; Bianchi F
Epidemiol Prev; 2012; 36(5 Suppl 1):1-104. PubMed ID: 23139155
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study.
La Mantia L; Benedetti MD; Sant M; d'Arma A; Di Tella S; Lillini R; Mendozzi L; Marangi A; Turatti M; Caputo D; Rovaris M
Neurol Sci; 2021 Dec; 42(12):5157-5163. PubMed ID: 33791892
[TBL] [Abstract][Full Text] [Related]
18. Cancer Incidence and Mortality Rates in Multiple Sclerosis: A Matched Cohort Study.
Marrie RA; Maxwell C; Mahar A; Ekuma O; McClintock C; Seitz D; Webber C; Groome PA
Neurology; 2021 Jan; 96(4):e501-e512. PubMed ID: 33239364
[TBL] [Abstract][Full Text] [Related]
19. Incidence of multiple sclerosis in the Republic of Ireland: A prospective population-based study.
O'Connell K; Tubridy N; Hutchinson M; McGuigan C
Mult Scler Relat Disord; 2017 Apr; 13():75-80. PubMed ID: 28427707
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of multiple sclerosis in France in 2021: Data from the French health insurance database.
Pierret C; Mainguy M; Leray E
Rev Neurol (Paris); 2024 May; 180(5):429-437. PubMed ID: 38423846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
